Effect of once-weekly semaglutide on the counterregulatory response to hypoglycaemia in people with type 2 diabetes: A randomized, placebo-controlled, double-blind, crossover trial

What Was Tested

The paper reports a study of Semaglutide, published as a randomized controlled trial.

To investigate the effects of semaglutide vs placebo on glucagon and other counterregulatory hormones during hypoglycaemia in type 2 diabetes (T2D).

Who Took Part

The study group was 38 men.

By PubMed's age tags, the people studied were adults and middle-aged adults, both men and women.

In this double-blind, placebo-controlled, single-centre trial, the researchers randomized 38 men and women (treated only with metformin) 1:1 to 2 12-week crossover periods of once-weekly subcutaneous semaglutide or placebo, each followed by a hypoglycaemic clamp procedure.

How the Study Was Run

The design is described as randomized, double-blind, placebo-controlled and crossover.

Because people in this Semaglutide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

Neither the men nor the staff measuring them knew who was on Semaglutide, so expectations could not easily colour the readings.

Some men received a placebo instead of Semaglutide, giving a reference point.

In the crossover set-up each of the men took both Semaglutide and the comparison in turn, acting as their own control.

What Was Measured

PubMed files the paper under topics including Blood Glucose, Diabetes Mellitus, Type 2, Glucagon-Like Peptides, Hypoglycemia and Semaglutide.

Author keywords: GLP-1, GLP-1 analogue, hypoglycaemia and type 2 diabetes.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Semaglutide in 38 men.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2018 (Diabetes, obesity & metabolism), a journal based in England.

More context: the Semaglutide compound page.